Pulmonary Sarcoidosis is an inflammatory lung disease of unknown cause with higher incidence in the age range of 20-50 years and among women. The leading symptoms of pulmonary sarcoidosis are cough and progressive shortness of breath due to decreased lung capacity. In some patients progression is faster and can end up with mortality associated with respiratory failure. It does not have a definitive treatment and only symptom-relieving therapies are applied currently.
A Phase III study led by Centurion Pharma has been initiated for this disease which does not have a definitive treatment. It has been planned to halt the progression of the disease by applying a natural protein to the respiratory tract via a device, which is a unique method in both Turkey and the rest of the world. Provided that positive outcomes are obtained from this study, the first local and original-patented product of Turkey in this field will be developed, along with being the only treatment choice in the world. Having been obtained positive results from Phase I studies in animal trials and in humans, this treatment is planned to be filed for regulatory approval in global scale after the Phase III studies, and then launched into the market in 2018.
Phase III clinical trials are planned to be initiated within 2016 for the treatment of other diseases such as Myasthenia Gravis and Systemic Lupus Erythematosus which do not have definitive therapies.